Incyte Aktie
| 91,32USD | 2,04USD | 2,28% |
WKN: 896133 / ISIN: US45337C1027
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 1 773 | 2 094 | 2 324 | 2 524 | 2 617 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1,50 | 1,43 | 1,46 | 1,46 | 1,62 |
Bilanz (in Mio. USD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 2 360 | 3 119 | 4 093 | 4 645 | 3 239 |
| Summe Anlagevermögen | 1 224 | 1 855 | 1 791 | 2 177 | 2 243 |
| Summe Aktiva | 3 584 | 4 974 | 5 884 | 6 822 | 5 482 |
Bilanz (in Mio. USD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 972 | 1 204 | 1 513 | 1 632 | 2 035 |
| Summe Eigenkapital | 2 611 | 3 770 | 4 370 | 5 190 | 3 448 |
| Summe Passiva | 3 584 | 4 974 | 5 884 | 6 822 | 5 482 |
Adresse
| 1801 Augustine Cut-Off, 19803 Wilmington | |
| Telefon | +1 (302) 498-6700 |
| Internet | http://www.incyte.com |
Management
|
Benjamin J. Strain
Head-Investor Relations |
|
Dave Gardner
Chief Strategy Officer & Executive Vice President |
|
Edmund P. Harrigan
Independent Director |
|
Herve Hoppenot
Director |
|
Jacqualyn A. Fouse
Independent Director |
|
Jean-Jacques Bienaimé
Independent Director |
|
Julian Charles Baker
Chairman |
|
Katherine A. High
Independent Director |
|
Keith Mikkelson
Executive Director-Business Development |
|
Lothar H. Finke
Group Vice President & General Manager |
|
Michael Morrissey
Executive VP & Head-Global Technical Operations |
|
Otis W. Brawley
Independent Director |
|
Pablo J. Cagnoni
Co-President, Head-Research & Development |
|
Paul J. Clancy
Independent Director |
|
Peter Langmuir
Vice President-Oncology Drug Development |
|
Sheila A. Denton
Secretary, Executive VP & General Counsel |
|
Soni Basi
Chief Human Resources Officer & Executive VP |
|
Steven H. Stein
Chief Medical Officer & Executive Vice President |
|
Susanne Antonie Schaffert
Independent Director |
|
Thomas Tray
Chief Financial & Accounting Officer |
|
Vijay Iyengar
EVP, Head-Global Medical Affairs & Product |
|
William J. Meury
Co-President, Chief Executive Officer & Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.